NASDAQ$TGTX
TG Therapeutics Inc. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
TG Therapeutics reported financial results for the fourth quarter and year ended December 31, 2022, and recent company developments.
TG Therapeutics reported product revenue of approximately zero for the fourth quarter of 2022. R&D expenses were $29.6 million, and SG&A expenses were $22.5 million. The net loss for the quarter was $53.0 million. Cash, cash equivalents and investment securities were $174.1 million as of December 31, 2022.
- BRIUMVI was approved by the FDA for the treatment of relapsing forms of multiple sclerosis (RMS).
- BRIUMVI was commercially launched and made available for patients and physicians.
- Additional data from the ULTIMATE I and II Phase 3 trials were presented at medical conferences.
- The company anticipates that its cash, cash equivalents and investment securities as of December 31, 2022, will be sufficient to fund planned operations into mid-2024.
Headline financials
Revenue & EPS history
TG Therapeutics · Revenue · Quarterly
$80K
Forward guidance
TG Therapeutics anticipates that its cash, cash equivalents and investment securities as of December 31, 2022, combined with available capacity under its existing term loan facility and projected revenues, will be sufficient to fund the Company’s planned operations into mid-2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+2.7%
Avg return
Earnings day
+5.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
49%
27 / 55 earnings
Positive
+81.0%
Q3 2022
Best reaction
-49.0%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +16.3% | +19.4% | +11.1% | |
| Q4 2025 | +4.3% | -2.6% | +7.0% | |
| Q3 2025 | -1.0% | -7.3% | -9.1% | |
| Q1 2025 | -13.4% | -22.6% | -14.7% | |
| Q4 2024 | +14.4% | +27.8% | +32.3% | |
| Q3 2024 | -3.9% | +7.1% | +25.9% | |
| Q2 2024 | +16.2% | +15.7% | +24.7% | |
| Q1 2024 | +20.2% | +20.9% | +19.3% | |
| Q4 2023 | +23.8% | +28.5% | +9.3% | |
| Q3 2023 | +34.7% | +32.6% | +78.9% | |
| Q2 2023 | -49.0% | -48.2% | -49.4% | |
| Q1 2023 | +25.5% | +38.1% | +7.2% | |
| Q4 2022 | -3.8% | +7.8% | -8.2% | |
| Q3 2022 | +81.0% | +70.7% | +45.7% | |
| Q2 2022 | +19.4% | +33.4% | +9.1% | |
| Q1 2022 | -10.9% | +1.4% | -24.5% | |
| Q4 2021 | +4.7% | -11.1% | -3.6% | |
| Q3 2021 | +7.9% | +5.3% | -52.5% | |
| Q2 2021 | -27.2% | -32.8% | -15.8% | |
| Q1 2021 | -6.7% | -14.8% | -7.2% | |
| Q4 2020 | -5.0% | -3.8% | +8.8% | |
| Q3 2020 | -0.2% | +4.4% | +5.0% | |
| Q2 2020 | -12.0% | +2.6% | +22.3% | |
| Q1 2020 | +5.9% | +2.6% | -6.0% | |
| Q4 2019 | -4.1% | -13.6% | -32.6% | |
| Q3 2019 | +1.4% | +2.7% | +20.6% | |
| Q2 2019 | +3.3% | +0.1% | -8.4% | |
| Q1 2019 | -15.5% | -13.4% | -8.0% | |
| Q4 2018 | +0.4% | -8.1% | +18.2% | |
| Q3 2018 | +2.5% | -1.1% | -4.4% | |
| Q2 2018 | -3.4% | -0.4% | +0.0% | |
| Q1 2018 | -3.7% | -2.6% | +3.7% | |
| Q4 2017 | +8.5% | +10.2% | -15.1% | |
| Q3 2017 | +9.9% | +9.3% | +12.6% | |
| Q2 2017 | +1.0% | +16.0% | +22.0% | |
| Q1 2017 | +2.5% | +11.3% | +36.5% | |
| Q4 2016 | +3.4% | +22.5% | -10.6% | |
| Q3 2016 | +1.0% | +6.7% | -1.9% | |
| Q2 2016 | -7.6% | -0.2% | +13.3% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -6.8% | — | — | |
| Q3 2015 | +8.4% | — | — | |
| Q2 2015 | -2.2% | — | — | |
| Q1 2015 | -6.0% | — | — | |
| Q3 2014 | +14.6% | — | — | |
| Q1 2012 | -3.7% | — | — | |
| Q2 2012 | -14.3% | — | — | |
| Q4 2011 | -23.0% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +36.4% | — | — | |
| Q4 2010 | +7.7% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro